CUE - Cue Biopharma rises on data for CUE-101 in head and neck cancer

Continuing its rise from Friday, shares of Cue Biopharma (NASDAQ:CUE) are up another 8% in premarket trading following data on its lead candidate CUE-101 for HPV+ head and neck cancer. The stock closed up 9.8% on Friday following release of the data. Shares are up 9.5% this morning in premarket trading. A presentation on Saturday at the Society for Immunotherapy of Cancer's 36th Annual Meeting examined CUE-101 alone and in combination with Keytruda (pembrolizumab). Results showed that as monotherapy, CUE-101 led to clinical benefit in 46.2% of patients and durable stable response in 38.5%. In a dose escalation study of three patients on CUE-101 + Keytruda, all showed tumor reduction after two cycles of therapy. Cue said it sees multiple registration paths for CUE-101: As a second-line therapy in head and neck cancer as monotherapy; first-line in combination with Keytruda; and as early treatment as a neoadjuvant therapy. Cue secured new patents for CUE-101 back

For further details see:

Cue Biopharma rises on data for CUE-101 in head and neck cancer